» Articles » PMID: 37828086

(B)On(e)-cohistones and the Epigenetic Alterations at the Root of Bone Cancer

Overview
Specialty Cell Biology
Date 2023 Oct 12
PMID 37828086
Authors
Affiliations
Soon will be listed here.
Abstract

Identification of mutations in histones in a number of human neoplasms and developmental syndromes represents the most compelling evidence to date for a causal role of epigenetic perturbations in human disease. In most cases, these mutations have gain of function properties that cause deviation from normal developmental processes leading to embryo defects and/or neoplastic transformation. These exciting discoveries represent a step-change in our understanding of the role of chromatin (dys)regulation in development and disease. However, the mechanisms of action of oncogenic histone mutations (oncohistones) remain only partially understood. Here, we critically assess existing literature on oncohistones focussing mainly on bone neoplasms. We show how it is possible to draw parallels with some of the cell-autonomous mechanisms of action described in paediatric brain cancer, although the functions of oncohistones in bone tumours remain under-investigated. In this respect, it is becoming clear that histone mutations targeting the same residues display, at least in part, tissue-specific oncogenic mechanisms. Furthermore, it is emerging that cancer cells carrying oncohistones can modify the surrounding microenvironment to support growth and/or alter differentiation trajectories. A better understanding of oncohistone function in different neoplasms provide potential for identification of signalling that could be targeted therapeutically. Finally, we discuss some of the main concepts and future directions in this research area, while also drawing possible connections and parallels with other cancer epigenetic mechanisms.

References
1.
Mohammad F, Helin K . Oncohistones: drivers of pediatric cancers. Genes Dev. 2018; 31(23-24):2313-2324. PMC: 5795778. DOI: 10.1101/gad.309013.117. View

2.
Lewis P, Muller M, Koletsky M, Cordero F, Lin S, Banaszynski L . Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134):857-61. PMC: 3951439. DOI: 10.1126/science.1232245. View

3.
Alghamri M, McClellan B, Avvari R, Thalla R, Carney S, Hartlage C . G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy. Sci Adv. 2021; 7(40):eabh3243. PMC: 8480930. DOI: 10.1126/sciadv.abh3243. View

4.
Arimura Y, Ikura M, Fujita R, Noda M, Kobayashi W, Horikoshi N . Cancer-associated mutations of histones H2B, H3.1 and H2A.Z.1 affect the structure and stability of the nucleosome. Nucleic Acids Res. 2018; 46(19):10007-10018. PMC: 6212774. DOI: 10.1093/nar/gky661. View

5.
Toledo R, Qin Y, Cheng Z, Gao Q, Iwata S, Silva G . Recurrent Mutations of Chromatin-Remodeling Genes and Kinase Receptors in Pheochromocytomas and Paragangliomas. Clin Cancer Res. 2015; 22(9):2301-10. PMC: 4854762. DOI: 10.1158/1078-0432.CCR-15-1841. View